Premium
Low‐dose α‐interferon treatment of chronic myeloid leukemia
Author(s) -
Sanchez Angel,
Robinson William A.,
Cohn Allen,
Gonzalez Rene,
Adlakha Arun
Publication year - 1992
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830390113
Subject(s) - medicine , myeloid leukemia , interferon , interferon alfa , gastroenterology , alpha interferon , interferon α , myeloid , leukemia , immunology
We treated 29 patients with chronic‐phase and accelerated chronic myeloid leukemia (CML) with α‐interferon in a dose of 2 mU/m 2 given subcutaneously daily for 30 days and then three times per week. Most had received prior treatment. Three patients have had sustained hematologic and karyotypic remissions after a median of 22 months of treatment. Three further patients have had complete hematologic and partial karyotypic remissions. At a median follow‐up of 48 months, the median survival has not been reached. This dose of α‐interferon may induce sustained remissions even in pretreated patients and may prolong survival in CML.